cIMPACT-NOW Update 3: Recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

By D. Brat, Kenneth D. Aldape, H. Colman, Eric C. Holland, D. Louis, R. Jenkins, B. Kleinschmidt-DeMasters, A. Perry, Guido Reifenberger, R. Stupp and 2 more. Acta Neuropathologica, 2018

744 citations recorded by the source corpus.

Working Committee 1 concluded that histologic grade II and III IDH-wildtype diffuse astrocytic gliomas that contain high-level EGFR amplification, the combination of whole chromosome 7 gain and whole chromosome 10 loss (+7/−10), or TERT promoter mutations, correspond to WHO grade IV and should be referred to as diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV. Assessment of classification by DNA methylation profiling and additional +7/−10 signatures appear to be promising as well and could be considered in the future following additional experience and validation. We also concluded that specific molecular signatures in subsets of IDH-wildtype diffuse astrocytic gliomas are associated with better clinical outcomes and should not lead to a high-grade designation, including, but not limited to, those gliomas with MYB/MYBL or BRAF alterations as individual drivers.

Subfields: Cancer Research, Genetics, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/6c8e12eae5fc02a3aa4127e23cf0c290c4ff83a5